4.6 Article

Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva

Journal

IMMUNOLOGY
Volume 164, Issue 1, Pages 135-147

Publisher

WILEY
DOI: 10.1111/imm.13349

Keywords

antibodies; COVID-19; ELISA; SARS-CoV-2

Categories

Funding

  1. Medical Research Council
  2. Global Challenges Research Fund (GCRF)
  3. Institute for Global Innovation (IGI) of the University of Birmingham [3107]
  4. UK National Institute for Health Research, Birmingham Biomedical Research Centres Funding scheme
  5. International AIDS Vaccine Initiative
  6. Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery [OPP1196345/INV-008813, OPP1084519, OPP1115782]
  7. Scripps Consortium for HIV Vaccine Development (CHAVD) (NIH: National Institute for Allergy and Infectious Diseases) [AI144462]
  8. University of Southampton Coronavirus Response Fund
  9. Welsh Clinical Academic Training (WCAT) programme
  10. University of Birmingham
  11. University Hospitals Birmingham NHS Foundation Trust

Ask authors/readers for more resources

Detecting antibody responses during and after SARS-CoV-2 infection is crucial in determining the seroepidemiology of the virus and the potential role of antibody in disease. Developing sensitive and specific serological assays, as well as detecting antibody responses in both saliva and serum, can contribute to understanding virus exposure and immune responses after infection.
Detecting antibody responses during and after SARS-CoV-2 infection is essential in determining the seroepidemiology of the virus and the potential role of antibody in disease. Scalable, sensitive and specific serological assays are essential to this process. The detection of antibody in hospitalized patients with severe disease has proven relatively straightforward; detecting responses in subjects with mild disease and asymptomatic infections has proven less reliable. We hypothesized that the suboptimal sensitivity of antibody assays and the compartmentalization of the antibody response may contribute to this effect. We systematically developed an ELISA, optimizing different antigens and amplification steps, in serum and saliva from non-hospitalized SARS-CoV-2-infected subjects. Using trimeric spike glycoprotein, rather than nucleocapsid, enabled detection of responses in individuals with low antibody responses. IgG1 and IgG3 predominate to both antigens, but more anti-spike IgG1 than IgG3 was detectable. All antigens were effective for detecting responses in hospitalized patients. Anti-spike IgG, IgA and IgM antibody responses were readily detectable in saliva from a minority of RT-PCR confirmed, non-hospitalized symptomatic individuals, and these were mostly subjects who had the highest levels of anti-spike serum antibodies. Therefore, detecting antibody responses in both saliva and serum can contribute to determining virus exposure and understanding immune responses after SARS-CoV-2 infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available